Please assess the completion status of the following clinical trial:

Trial Title: Miradry Treatment for Focal Axillary Hyperhidrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~This study will recruit patients diagnosed with focal hyperhidrosis with a known diagnosis of primarily axillary localization.~We will only enroll patients available for both treatment visits. Availability for follow-up visit is optional.~Only patients between the ages of 18 and 29 years when the first HHIQ is administered will be eligible.~The upper age limit was so determined because patients over 29 years often present with psychopathology which is far more recalcitrant to correction of any kind regardless of effectiveness because of the duration of the condition.~The lower age limit was so determined because 18 years and up are the ages for which the miraDry ® procedure has been approved for use by the FDA.~All participants will be screened using the Hyperhidrosis Disease Severity Scale (HDSS).~Only patients reporting their condition as a 3 out of 4 or higher on the HDSS will be eligible for study because preliminary data suggests effective detection of psychological changes only at higher reported levels of sweating severity.~A patient's previous non-invasive treatment course, including but not limited to prescription of psychiatric medication and topical therapies, will not justify exclusion from this study.~Exclusion Criteria:~Patients who are unable to provide informed consent, have known allergies to lidocaine, hibiclens with 4% chlorhexidine, and/or epinephrine, are pregnant (as determined by self-reporting), are unable to take oral antibiotics or antiseptic washes, have heart pacemakers or other electronic device implants, and who need supplemental oxygen are not eligible to participate in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 29 Years
- Healthy Volunteers: f

Study Arms:
- MiraDry ® treatment (Type: EXPERIMENTAL): MiraDry ® is the trademarked name of a non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface.~Each participant will be scheduled two MiraDry ® treatment appointments approximately three months apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).